Aton Ra Partners Intellia Therapeutics, Inc. Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 7,502 shares of NTLA stock, worth $91,374. This represents 0.45% of its overall portfolio holdings.

Number of Shares

7,502

Previous 8,370 10.37%

Holding current value

$91,374

Previous $264,000 13.64%

% of portfolio

0.45%

Previous 0.55%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$23.16 - $32.34 $20,102 - $28,071	-868 Reduced 10.37%	7,502 $228,000
Q3 2023 Oct 25, 2023	SELL	$31.62 - $45.78 $57,042 - $82,587	-1,804 Reduced 17.73%	8,370 $264,000
Q2 2023 Jul 18, 2023	SELL	$34.58 - $46.03 $24,655 - $32,819	-713 Reduced 6.55%	10,174 $414,000
Q1 2023 May 05, 2023	SELL	$33.3 - $44.82 $48,118 - $64,764	-1,445 Reduced 11.72%	10,887 $405,000
Q4 2022 Feb 02, 2023	SELL	$33.21 - $62.69 $151,171 - $285,364	-4,552 Reduced 26.96%	12,332 $430,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $6,146 - $8,173	114 Added 0.68%	16,884 $945,000
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $123,552 - $244,634	-3,210 Reduced 16.07%	16,770 $868,000
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $559,741 - $1.14 Million	-9,606 Reduced 32.47%	19,980 $1.45 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $345,909 - $474,989	3,433 Added 13.13%	29,586 $3.5 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $857,360 - $1.15 Million	6,477 Added 32.92%	26,153 $3.51 Million
Q2 2021 Aug 12, 2021	BUY	$60.88 - $161.91 $520,280 - $1.38 Million	8,546 Added 76.78%	19,676 $3.19 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $518,546 - $931,358	11,130 New	11,130 $893,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account